NEW YORK (GenomeWeb News) – The US Court of Appeals for the Federal Circuit has upheld a lower court's ruling that Affymetrix and Life Technologies' Navigenics business did not infringe a patent held by E8 Pharmaceuticals and the Massachusetts Institute of Technology.

The court issued its ruling last week saying it was based "solely on our agreement with the district court's construction of the phrase 'randomly primed PCR-derived RCG.' We do not reach any other issues raised on appeal."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.